title: Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model.
abstract: OBJECTIVE
  Recent experimental and clinical studies on Parkinson's disease point out the pivotal role of inflammation in the pathogenesis of neurodegeneration and the possible positive effects of nonsteroidal anti-inflammatory drug therapies. Our aim in this study was to investigate the preventive effects of nonsteroidal anti-inflammatory drugs in the 6-hydroxydopamine (6-OHDA) induced rat model of Parkinson's disease.
  
  
  METHODS
  Twenty-one female Wistar-Albino rats (200-250g) were used in this study. The rats were divided in three groups: Saline group (n: 7, 2 ml), Acetylsalicylic acid group (n: 7, 100 mg/kg), and Meloxicam group (n: 7, 50 mg/kg). An hour after administration, the rats received a unilateral intranigral injection of 6-OHDA to produce the Parkinson model lesion. Rotational tests were performed two weeks later as follow-up. Immunohistochemical tests were performed in all groups to determine the severity of the lesion in the substantia nigra.
  
  
  RESULTS
  Administration of drugs an hour before the lesions were created did not protect the degeneration of dopaminergic neurons in the substantia nigra.
  
  
  CONCLUSIONS
  Oral usage of low repeated doses of nonsteroidal anti-inflammatory drugs may possibly slow down the progression of the disease.
authors.affiliation: Uludag University School of Medicine, Department of Physiology, Bursa, Turkey. bgoren@uludag.edu.tr
authors.forename: Bülent
authors.initials: B
authors.lastname: Gören
authors.forename: Zehra
authors.initials: Z
authors.lastname: Mimbay
authors.forename: Nebahat
authors.initials: N
authors.lastname: Bilici
authors.forename: Mehmet
authors.initials: M
authors.lastname: Zarifoğlu
authors.forename: Erhan
authors.initials: E
authors.lastname: Oğul
authors.forename: Ender
authors.initials: E
authors.lastname: Korfali
mesh_terms: D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D007150:Immunohistochemistry; D000077239:Meloxicam; D018696:Neuroprotective Agents / Q000494:pharmacology*; D016627:Oxidopamine / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013565:Sympatholytics / Q000633:toxicity; D013843:Thiazines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D000662:Amphetamines; D000978:Antiparkinson Agents; D016861:Cyclooxygenase Inhibitors; D018696:Neuroprotective Agents; D013565:Sympatholytics; D013843:Thiazines; D013844:Thiazoles; D016627:Oxidopamine; D001058:Apomorphine; D001241:Aspirin; D000077239:Meloxicam